Newsletter - Alzheimer Europe October 2020 newsletter https://alzheimereurope.newsweaver.com/Newsletter/ en-us 03 Nov 2020 02:30:06 CET 03 Nov 2020 02:30:06 CET https://alzheimereurope.newsweaver.com/Newsletter/rss.xml Newsweaver info@alzheimer-europe.org () support@newsweaver.ie (Newsweaver) 60 true Welcome https://alzheimereurope.newsweaver.com/Newsletter/17gwncm395m?lang=en?rss=true Alzheimer Europe’s October 2020 [ https://alzheimereurope.newsweaver.com/Newsletter/mwtjzk2irak/external ] newsletter [ https://alzheimereurope.newsweaver.com/Newsletter/mwtjzk2irak/external ] [ https://alzheimereurope.newsweaver.com/Newsletter/mwtjzk2irak/external ] brings you the latest news on developments in the dementia field, across Europe and beyond. Summaries of a few of our top stories appear below. Our monthly newsletter reaches around 11,000 people and we are always happy to receive feedback, or suggestions regarding news items to share in future issues. Click here to download full newsletter [ https://alzheimereurope.newsweaver.com/Newsletter/mwtjzk2irak/external ] [ https://alzheimereurope.newsweaver.com/Newsletter/mwtjzk2irak/external ] 03 Nov 2020 12:00:00 CET 0ab0c135e53fc5c9fb32288b3fdc41a9 Feature Article <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v2files/shard1/56305/2b/92a8976269fb1f449eddd2.jpg" style="margin: 5px;" width="150" height="100" hspace="5" vspace="5" alt="" />Alzheimer Europe’s <a href="https://alzheimereurope.newsweaver.com/Newsletter/mwtjzk2irak/external" target="_blank" rel="noopener"><strong>October 2020</strong> <strong>newsletter</strong></a> brings you the latest news on developments in the dementia field, across Europe and beyond.</p> <p style="text-align: justify;">Summaries of a few of our top stories appear below.</p> <p style="text-align: justify;">Our monthly newsletter reaches around 11,000 people and we are always happy to receive feedback, or suggestions regarding news items to share in future issues.</p> <p style="text-align: justify;"> </p> <p style="text-align: justify;"><a href="https://alzheimereurope.newsweaver.com/Newsletter/mwtjzk2irak/external" target="_blank" rel="noopener"><strong>Click here to download full newsletter</strong></a></p> 1 October: Sirpa Pietikainen MEP submits written question on dementia https://alzheimereurope.newsweaver.com/Newsletter/qlwub4omwf8?lang=en?rss=true European Alzheimer’s Alliance Chairperson and member of the Alzheimer Europe Board, Sirpa Pietikainen MEP (EPP, Finland), has submitted a written question to the European Commission asking about the place of dementia in the future priorities of the EU. 03 Nov 2020 12:00:00 CET 4b2df2f66d077a132160c1d027294cb4 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v2files/shard1/56305/68/9dc012584cbda777794db9.jpg" style="margin: 5px;" width="150" height="110" hspace="5" vspace="5" alt="" />European Alzheimer’s Alliance Chairperson and member of the Alzheimer Europe Board, Sirpa Pietikainen MEP (EPP, Finland), has submitted a written question to the European Commission asking about the place of dementia in the future priorities of the EU.</p> <p style="text-align: justify;"> </p> <p style="text-align: justify;"> </p> <p style="text-align: justify;"> </p> <p style="text-align: justify;"> </p> https://www.alzheimer-europe.org/News/European-Alzheimer-s-Alliance/Thursday-01-October-2020-Sirpa-Pietikainen-MEP-submits-written-question-on-dementia 5 October: Alzheimer Europe AGM elects new Board https://alzheimereurope.newsweaver.com/Newsletter/heg7zmaitrx?lang=en?rss=true Alzheimer Europe’s Annual General Meeting (AGM) was held online, on 5 October 2020. Chaired by Iva Holmerová, the meeting was attended by representatives of 28 out of 35 full member associations and 2 provisional member associations.Delegates with full voting rights elected a new Alzheimer Europe Board for the term 2020-2022. 03 Nov 2020 12:00:00 CET 2376eb43d5326404ffdfdbde36fd6280 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v2files/shard1/56305/fe/ea658c0a2b67995a44891a.jpg" style="margin: 5px;" width="150" height="67" hspace="5" vspace="5" alt="" />Alzheimer Europe’s Annual General Meeting (AGM) was held online, on 5 October 2020. Chaired by Iva Holmerová, the meeting was attended by representatives of 28 out of 35 full member associations and 2 provisional member associations.Delegates with full voting rights elected a new Alzheimer Europe Board for the term 2020-2022.</p> https://www.alzheimer-europe.org/News/Alzheimer-Europe/Monday-05-October-2020-AGM-elects-new-Board-says-farewell-to-Helen-Rochford-Brennan-and-welcomes-Hungary-as-a-full-member 20 October: Alzheimer Europe holds its first ever virtual Annual Conference #30AEC https://alzheimereurope.newsweaver.com/Newsletter/1c2hm4xd6cq?lang=en?rss=true The 30th Alzheimer Europe Conference (#30AEC) “Dementia in a changing world” was held online from 20-22 October 2020. Almost 800 participants, from 42 countries, attended the conference, which boasted 260 speakers and 100 poster presentations, sharing their research, projects and experiences in an atmosphere of collaboration and solidarity, against the backdrop of the global COVID-19 pandemic. 03 Nov 2020 12:00:00 CET 98b8a166c227a19cc4f093de6a8733dc Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v2files/shard1/56305/8c/ce4e123ee1c4f3db4e8f3d.jpg" style="margin:0px;" width="150" height="100" hspace="0" vspace="0" alt="" />The 30<sup>th</sup> Alzheimer Europe Conference (#30AEC) “Dementia in a changing world” was held online from 20-22 October 2020. Almost 800 participants, from 42 countries, attended the conference, which boasted 260 speakers and 100 poster presentations, sharing their research, projects and experiences in an atmosphere of collaboration and solidarity, against the backdrop of the global COVID-19 pandemic.</p> https://www.alzheimer-europe.org/News/Alzheimer-Europe/Tuesday-20-October-2020-Alzheimer-Europe-holds-its-first-ever-virtual-Annual-Conference-30AEC 23 October: European Working Group of People with Dementia begins new term https://alzheimereurope.newsweaver.com/Newsletter/pfyrk376wwz?lang=en?rss=true The European Working Group of People with Dementia (EWGPWD) began its fifth two-year term of office with an online meeting on 23 October 2020. During this meeting, the group welcomed six new members. 03 Nov 2020 12:00:00 CET acd36f6e3a8c4085139448442e641979 Other Articles <p><img align="left" src="http://alzheimereurope.newsweaver.com/v2files/shard1/56305/41/62e5b77fcce14665780126.jpg" style="margin: 5px;" width="150" height="54" hspace="5" vspace="5" alt="" />The European Working Group of People with Dementia (EWGPWD) began its fifth two-year term of office with an online meeting on 23 October 2020. During this meeting, the group welcomed six new members.</p> <p> </p> https://www.alzheimer-europe.org/News/Alzheimer-Europe/Friday-23-October-2020-European-Working-Group-of-People-with-Dementia-holds-first-meeting-of-new-group-for-2020-2022-term 30 October: EMA accepts to review Biogen's Marketing Authorisation Application for aducanumabeview bz EMA https://alzheimereurope.newsweaver.com/Newsletter/doc8mv4yeya?lang=en?rss=true This month, Biogen disclosed that it had submitted a European Medicines Agency (EMA) Marketing Authorisation Application (MAA) for aducanumab, a monoclonal β-amyloid antibody that has been evaluated in several Phase 2 and 3 clinical trials on mild Alzheimer’s disease and mild cognitive impairment (MCI). The EMA had accepted the MAA for review, following a standard timetable. 03 Nov 2020 12:00:00 CET e4856fa751111668a319c1f090cc7dd2 Other Articles <p><img align="left" src="http://alzheimereurope.newsweaver.com/v2files/shard1/56305/b2/cae68b187475343dfbe90d.jpg" style="margin: 5px;" width="150" height="72" hspace="5" vspace="5" alt="" />This month, Biogen disclosed that it had submitted a European Medicines Agency (EMA) Marketing Authorisation Application (MAA) for aducanumab, a monoclonal β-amyloid antibody that has been evaluated in several Phase 2 and 3 clinical trials on mild Alzheimer’s disease and mild cognitive impairment (MCI). The EMA had accepted the MAA for review, following a standard timetable.</p> https://www.alzheimer-europe.org/News/Science-watch/Friday-30-October-2020-Marketing-authorisation-application-for-Aducanumab-accepted-by-European-Medicines-Agency